ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 11.38K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 375.00 shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was -140.92K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 0.00 shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 2.88K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-06-30 | 11.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2023-03-31 | 375.00 shares 10-Q · filed 2023-05-15 | |
| 2021-12-31 | -140.92K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09 | 2.88K shares 10-K/A · filed 2023-06-09 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |